Aim. The present study was conducted to determine the glycaemic effects of sitagliptin in type 2 diabetes patients. Methods. Data was collected from patient medical records of a major teaching hospital in Malaysia, from 2009 to 2012. Glycated hemoglobin (HbA1c) values prior to and up to 12 months after the initiation of sitagliptin were analysed. The change in HbA1c values was accounted for based on a generalized linear model generated using the Generalized Estimating Equations (GEE) method. Results and Discussion. Of the 457 patients, 53.6% were elderly and 81.4% were overweight. The mean HbA1c (standard deviation) before initiation of sitagliptin was 8.5 (1.4)%. This dropped to 7.7 (1.4)%, 3 to 6 months after initiation of sitagliptin, with a mean difference of 0.8% (95% confidence interval (CI): 0.7–1.0; P < 0.001). However, this value increased to 8.0 (1.7)% after 7 to 12 months on sitagliptin (P = 0.002) with a mean difference from baseline of 0.6% (95% CI: 0.4–0.7; P < 0.001). Conclusion. In routine clinical practice, sitagliptin produces a significant reduction in mean HbA1c (0.8%) within the first 6 months of use which corresponds to efficacy data obtained in controlled clinical trials. However, this reduction was lesser, 7 to 12 month later.
展开▼
机译：目标。进行本研究以确定西他列汀在2型糖尿病患者中的血糖作用。方法。数据收集自2009年至2012年马来西亚一家主要教学医院的患者病历。分析了西他列汀治疗开始前和治疗后12个月的糖化血红蛋白（HbA1c）值。 HbA1c值的变化是根据使用广义估计方程（GEE）方法生成的广义线性模型计算的。结果与讨论。在457例患者中，老人占53.6％，超重占81.4％。西他列汀开始治疗前的平均HbA1c（标准差）为8.5（1.4）％。西他列汀开始后3到6个月下降到7.7（1.4）％，平均差异为0.8％（95％置信区间（CI）：0.7-1.0； P <0.001）。但是，使用西他列汀7到12个月后，该值增加到8.0（1.7）％（P = 0.002），与基线的平均差为0.6％（95％CI：0.4-0.7; P <0.001）。结论。在常规临床实践中，西他列汀在使用后的头6个月内平均HbA1c显着降低（0.8％），这与对照临床试验中获得的功效数据相对应。但是，减少幅度较小，为7到12个月后。
展开▼
